ReviewFrontiers in endocrinology2026
Androgen and glucocorticoid crosstalk in granulosa cells: molecular insights into polyendocrine metabolic ovarian syndrome.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome (PCOS) is a multifaceted endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. At the cellular level, impaired folliculogenesis represents a key feature, with granulosa cells failing to optimally support follicle maturation, steroidogenesis, and oocyte competence. This review evaluates the hypothesis that granulosa cell dysfunction in PMOS may, in selected phenotypes, be prompted by altered molecular crosstalk between the androgen receptor and the glucocorticoid receptor. These two nuclear receptors integrate reproductive, metabolic, and stress-related signals within the ovarian microenvironment. Because androgen and glucocorticoid receptors share partially overlapping DNA-binding motifs and co-regulatory networks, their interaction may shape transcriptional programs governing proliferation, steroidogenesis, mitochondrial metabolism, and stress adaptation. Emerging evidence also highlights the contribution of adrenal-derived 11-oxygenated androgens, potent androgen receptor agonists, which amplify androgen signaling and reinforce the hyperandrogenic milieu. By integrating evidence from molecular, experimental, and patient-derived studies, this review proposes androgen and glucocorticoid receptor crosstalk as a plausible and testable regulatory framework, in PMOS pathophysiology with potential implications for biomarker discovery and future mechanism-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.